Vor Bio Announces $75 Million Private Placement with TCGX

Vor Bio (Nasdaq: VOR) entered a securities purchase agreement to sell 5,338,078 shares at $14.05 per share in a private placement led by new investor TCGX, expected to raise approximately $75 million before fees.

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) entered a securities purchase agreement to sell 5,338,078 shares at $14.05 per share in a private placement led by new investor TCGX, expected to raise approximately $75 million before fees. Closing is expected on or about March 30, 2026, subject to customary conditions.

Vor Bio intends to use net proceeds to advance global Phase 3 trials for telitacicept in myasthenia gravis and primary Sjögren’s disease, for business development, and for working capital; registration rights were granted for resale of the shares.

Positive

• $75 million gross proceeds expected from the private placement
• Financing led by new institutional investor TCGX
• Proceeds earmarked to advance global Phase 3 trials for telitacicept

Negative

• Issuance of 5,338,078 shares will dilute existing shareholders

Argus Mar 27 session

+6.71% close to close Open Argus

Details

News Market Reaction – VOR

In the Mar 27 session, VOR gained 6.71%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.7% in the session following this news. A strong positive reaction aligns with Vor...

Analysis

The stock moved +6.7% in the session following this news. A strong positive reaction aligns with Vor Bio’s history of financing-driven moves; prior private placements around telitacicept averaged 45.15% one-day gains. This deal adds about $75 million in gross proceeds atop earlier PIPEs, while an effective S-3 already covers resale of prior placement shares. Investors have previously treated such raises as validation of institutional support, though secondary selling and capital needs remained ongoing considerations.

Key Figures

Private placement shares: 5,338,078 shares Offering price: $14.05 per share Gross proceeds: approximately $75 million +1 more

Private placement shares

5,338,078 shares

Common stock issued in March 2026 private placement

Offering price

$14.05 per share

Price for March 2026 private placement

Gross proceeds

approximately $75 million

Expected gross proceeds before expenses from March 2026 private placement

Expected closing date

March 30, 2026

Targeted closing for private placement, subject to conditions

Previous Private placement Reports

4 past events · Latest: Dec 15

Same Type 4 events

1. Dec 15

   $150M private placement

   24h Move

   +8.0%

   Raised $150M via common stock to fund telitacicept Phase 3 programs.

2. Jun 26

   License + $175M PIPE

   24h Move

   +60.5%

   Exclusive telitacicept license and $175M private placement supported global trials.

3. Jun 25

   $175M prefunded PIPE

   24h Move

   +60.5%

   Announced $175M prefunded warrant placement to fund clinical pipeline.

4. Dec 27

   $55.6M PIPE financing

   24h Move

   +51.5%

   Secured $55.6M PIPE with warrants, extending runway for 2025 trial readouts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, securities purchase agreement, BAFF/APRIL inhibition, Phase 3, +3 more

7 terms

private placement financial

"sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

securities purchase agreement financial

"announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

BAFF/APRIL inhibition medical

""BAFF/APRIL inhibition represents one of the next major waves of innovation in autoimmune disease""

BAFF/APRIL inhibition is a drug strategy that blocks two immune signaling proteins, BAFF and APRIL, which help B cells survive and produce antibodies. Investors care because drugs using this mechanism aim to calm overactive immune responses in autoimmune diseases or reduce malignant B‑cell growth; clinical trial results, safety issues, and potential patient numbers can strongly affect a drug developer’s outlook—like cutting power to a malfunctioning device to stop damage, with trade‑offs to monitor.

Phase 3 medical

"With compelling Phase 3 data across multiple indications and tens of thousands of patients treated"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

generalized myasthenia gravis medical

"accelerate our efforts in generalized myasthenia gravis and, importantly, advance primary Sjögren’s disease"

A chronic neurological condition in which the immune system disrupts the chemical signals between nerves and muscles, causing muscle weakness that typically fluctuates and worsens with activity. Think of it as a faulty light switch or loose wiring that prevents muscles from responding reliably; severity and daily variability make treatment and long-term management important. For investors, the condition matters because it defines patient need, market size, and demand for approved therapies, clinical trial outcomes, and reimbursement decisions that drive company valuation.

primary Sjögren’s disease medical

"accelerate our efforts in generalized myasthenia gravis and, importantly, advance primary Sjögren’s disease"

Primary Sjögren’s disease is a chronic autoimmune condition in which the body’s immune system mistakenly attacks moisture-producing glands, causing persistent dry eyes and mouth and sometimes affecting joints, lungs, or kidneys. For investors, it matters because the condition represents a defined patient population with ongoing medical needs, driving demand for diagnostic tests, new therapies, and long-term treatment revenue—similar to how a widespread mechanical fault creates steady demand for a particular repair service.

registration rights agreement regulatory

"entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions.

The financing is led by new investor TCGX.

"BAFF/APRIL inhibition represents one of the next major waves of innovation in autoimmune disease, and telitacicept is at the forefront of the field. With compelling Phase 3 data across multiple indications and tens of thousands of patients treated in China, we believe telitacicept's clinical profile and robust safety data to date provide a unique opportunity to bring a differentiated, potentially disease-modifying therapy to patients globally,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “This financing enables us to accelerate our efforts in generalized myasthenia gravis and, importantly, advance primary Sjögren’s disease as a key next frontier – two large, multi-billion-dollar opportunities where significant unmet need remains and where we believe telitacicept can meaningfully change the treatment paradigm. We are well positioned to deliver on our commitment to maximize the impact of telitacicept for patients and drive long-term value for shareholders.”

“Our investment reflects the conviction we have in the Vor Bio team and the disruptive potential of telitacicept," said Cariad Chester, Managing Partner at TCGX. “With its differentiated efficacy profile, we believe telitacicept has the potential to become a foundational therapy for multiple B-cell mediated diseases. We are excited to support the pivotal development program of telitacicept and help build Vor Bio into a global leader in treating autoimmune diseases.”

Vor Bio intends to use the net proceeds from the private placement to advance the clinical development of telitacicept, including the ongoing global Phase 3 clinical trials for myasthenia gravis and primary Sjögren's disease, business development, and for working capital and general corporate purposes.

The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with entering into the securities purchase agreement, Vor Bio and the investors entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

About TCGX
TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in pioneering healthcare companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in San Francisco, Palo Alto, and New York City. For more information, please visit: www.tcgcrossover.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the private placement, including expected proceeds, expected use of proceeds and expected closing of the private placement; the potential of telitacicept and the BAFF/APRIL inhibition, Vor Bio’s opportunity to bring a differentiated, potentially disease-modifying therapy to patients globally, telitacicept’s potential to meaningfully change the treatment paradigm and become a foundational therapy for multiple B-cell mediated diseases, our market opportunities, and other statements that are not historical fact.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including market conditions and failure of customary closing conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. The results of the clinical trial described in this press release is based on information reported by RemeGen; Vor Bio has not independently verified this data.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing did Vor Bio (VOR) announce on March 27, 2026?

Vor Bio announced a private placement to sell 5,338,078 shares at $14.05 per share. According to the company, the transaction is led by TCGX and is expected to generate approximately $75 million gross proceeds before expenses.

When is the VOR private placement expected to close and what conditions apply?

The private placement is expected to close on or about March 30, 2026, subject to customary closing conditions. According to the company, closing depends on satisfaction of those conditions and customary closing deliverables.

How will Vor Bio use the proceeds from the $75 million VOR private placement?

Vor Bio intends to use net proceeds to advance clinical development, including ongoing global Phase 3 trials for myasthenia gravis and primary Sjögren’s disease. According to the company, funds will also support business development and general corporate purposes.

Who is the lead investor in Vor Bio’s March 27, 2026 financing and what did they say?

The financing is led by new investor TCGX, which expressed conviction in telitacicept’s potential. According to the company, TCGX cited telitacicept’s differentiated efficacy and support for pivotal development programs.

Will the VOR shares from the private placement be registered for resale?

Vor Bio entered a registration rights agreement and agreed to file a registration statement for resale of the issued shares. According to the company, resale registration will permit investors to sell the shares following SEC registration or an applicable exemption.

Did Vor Bio use a placement agent for the $75 million private placement (VOR)?

Vor Bio did not engage a placement agent in connection with the private placement. According to the company, the transaction was conducted without a placement agent and was led directly by investor TCGX.